AIMS: To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with European Union (EU)-approved Humira and US-licensed Humira after single subcutaneous doses in healthy subjects. METHODS: In a randomized, double-blind, parallel-group study, 180 healthy subjects received bysubcutaneous injection 40 mg of EU-Humira, or US-Humira, or FKB327, in a 1:1:1 ratio, stratified by bodyweight. Pharmacokinetics, local tolerability, immunogenicity, adverse events, vital signs, electrocardiography and laboratory safety tests were assessed prior to and up to 1536 h after treatment. RESULTS: The pharmacokinetics of FKB327 were similar to those of both EU- and US-Humira. The 90% confidence interval for the ratios of AUC0-t , AUC0-inf , and Cmax geometric means were in the acceptance range for bioequivalence of 0.80-1.25 for all three pairwise comparisons by analysis of covariance with baseline characteristics age, body weight and (for Cmax only) sex as covariates. Tolerability of all three treatments was equally acceptable, and there were no differences in safety profile or immunogenicity among the three treatments. Overall, antidrug antibodies were detected in approximately 70% of subjects who received each treatment; higher titres were associated with faster elimination of adalimumab. CONCLUSIONS: The study demonstrated pharmacokinetic similarity of FKB327 with EU- and US-Humira. FKB327 was well tolerated by healthy subjects, with adverse effects similar to Humira. If clinical similarity to Humira, including efficacy, can be shown in patients, FKB327 will meet the criteria for biosimilarity to Humira.
RCT Entities:
AIMS: To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with European Union (EU)-approved Humira and US-licensed Humira after single subcutaneous doses in healthy subjects. METHODS: In a randomized, double-blind, parallel-group study, 180 healthy subjects received by subcutaneous injection 40 mg of EU-Humira, or US-Humira, or FKB327, in a 1:1:1 ratio, stratified by bodyweight. Pharmacokinetics, local tolerability, immunogenicity, adverse events, vital signs, electrocardiography and laboratory safety tests were assessed prior to and up to 1536 h after treatment. RESULTS: The pharmacokinetics of FKB327 were similar to those of both EU- and US-Humira. The 90% confidence interval for the ratios of AUC0-t , AUC0-inf , and Cmax geometric means were in the acceptance range for bioequivalence of 0.80-1.25 for all three pairwise comparisons by analysis of covariance with baseline characteristics age, body weight and (for Cmax only) sex as covariates. Tolerability of all three treatments was equally acceptable, and there were no differences in safety profile or immunogenicity among the three treatments. Overall, antidrug antibodies were detected in approximately 70% of subjects who received each treatment; higher titres were associated with faster elimination of adalimumab. CONCLUSIONS: The study demonstrated pharmacokinetic similarity of FKB327 with EU- and US-Humira. FKB327 was well tolerated by healthy subjects, with adverse effects similar to Humira. If clinical similarity to Humira, including efficacy, can be shown in patients, FKB327 will meet the criteria for biosimilarity to Humira.
Authors: Niko K Bender; Christoph E Heilig; Benjamin Dröll; Jessica Wohlgemuth; Franz-Paul Armbruster; Bernhard Heilig Journal: Rheumatol Int Date: 2006-09-28 Impact factor: 2.631
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Petra Baji; Márta Péntek; László Czirják; Zoltán Szekanecz; György Nagy; László Gulácsi; Valentin Brodszky Journal: Eur J Health Econ Date: 2014-05-16
Authors: Vibeke Strand; Joao Gonçalves; Timothy P Hickling; Heather E Jones; Lisa Marshall; John D Isaacs Journal: BioDrugs Date: 2020-02 Impact factor: 5.807
Authors: Jan Hillson; Tim Mant; Molly Rosano; Carolyn Huntenburg; Mehrshid Alai-Safar; Siddhesh Darne; Donna Palmer; Borislava G Pavlova; Jennifer Doralt; Russell Reeve; Niti Goel; Doris Weilert; Paul W Rhyne; Kamali Chance; John Caminis; James Roach; Tanmoy Ganguly Journal: Pharmacol Res Perspect Date: 2018-02
Authors: Mark C Genovese; Josephine Glover; Maria Greenwald; Wieslawa Porawska; Elias Chalouhi El Khouri; Eva Dokoupilova; Juan Ignacio Vargas; Mykola Stanislavchuk; Herbert Kellner; Elena Baranova; Nobuhito Matsunaga; Rieke Alten Journal: Arthritis Res Ther Date: 2019-12-12 Impact factor: 5.156
Authors: Rieke Alten; Colin Markland; Malcolm Boyce; Kazuki Kawakami; Rafael Muniz; Mark C Genovese Journal: Int J Rheum Dis Date: 2020-08-27 Impact factor: 2.454
Authors: Kyung-Sang Yu; In-Jin Jang; Hyeong-Seok Lim; Jang Hee Hong; Min-Gul Kim; Min Kyu Park; Doo-Yeoun Cho; Min Soo Park; Jae Yong Chung; Jong-Lyul Ghim; SeungHwan Lee; Seok Kyu Yoon; In Sun Kwon; Sang Joon Lee; Sung Hyun Kim; Yun Ju Bae; Jung Bin Cha; Daniel E Furst; Edward Keystone; Jonathan Kay Journal: Clin Transl Sci Date: 2021-03-02 Impact factor: 4.689
Authors: Jing Yang; Jason D Lickliter; Jan L Hillson; Gary D Means; Russell J Sanderson; Kay Carley; Almudena Tercero; Kristi L Manjarrez; Jennifer R Wiley; Stanford L Peng Journal: Clin Transl Sci Date: 2021-03-02 Impact factor: 4.689